As coronavirus cases continue to decline in the UK, Oxford scientists are doing human trials for a possible coronavirus vaccine in Africa and Brazil, where more people are being exposed to the virus.

South Africa has nearly one-third of Africa’s confirmed cases with more than 106,000, including more than 2,100 deaths. In addition to the current human trials of 10,000 people, U.S. Oxford’s pharmaceutical partner AstraZeneca is planning to enroll 30,000 people starting this month after receiving $1 billion in investment from the U.S. government. If the vaccine works, they are planning to to make some 300 million doses of the vaccine available in the U.S. before the end of the year and 2 billion doses available in other countries by early next year.